Summary
Cyclin D1 is one of the G1 cyclins that control cell cycle progression by allowing G1 to S transition. Overexpression of cyclin D1 has been postulated to play an important role in the development of human cancers. We have investigated the correlation between cyclin D1 overexpression and known clinicopathological factors and also its prognostic implication on resected non-small-cell lung cancer (NSCLC) patients. Formalin-fixed and paraffin-embedded tumour tissues resected from 69 NSCLC patients between stages I and IIIa were immunohistochemically examined to detect altered cyclin D1 expression. Twenty-four cases (34.8%) revealed positive immunoreactivity for cyclin D1. Cyclin D1 overexpression is significantly higher in patients with lymph node metastasis (50.0% vs 14.4%, P = 0.002) and with advanced pathological stages (I, 10%; II, 53.8%; IIIa, 41.7%, P = 0.048; stage I vs II, IIIa, P = 0.006). Twenty-four patients with cyclin D1-positive immunoreactivity revealed a significantly shorter overall survival than the patients with negativity (24.0 ± 3.9 months vs 50.1 ± 6.4 months, P = 0.0299). Among 33 patients between stages I and II, nine patients with cyclin D1-positive immunoreactivity had a much shorter overall survival (29.7 ± 6.1 months vs 74.6 ± 8.6 months, P = 0.0066). These results suggest that cyclin D1 overexpression is involved in tumorigenesis of NSCLCs from early stage and could be a predictive molecular marker for poor prognosis in resectable NSCLC patients, which may help us to choose proper therapeutic modalities after resection of the tumor.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adelaide, J, Monges, G, Derderian, C, Seitz, JF & Birnbaum, D (1995). Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. Br J Cancer 71: 64–68.
Åkervall, JA, Michalides, RJ, Mineta, H, Balm, A, Borg, Å, Dictor, MR, Jin, Y, Loftus, B, Mertens, F & Wennerberg, JP (1997). Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 79: 380–389.
Bartkova, J, Lukas, J, Strauss, M & Bartek, J (1994). Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J Pathol 172: 237–245.
Bartkova, J, Lukas, J, Strauss, M & Bartek, J (1995). Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10: 775–778.
Betticher, DC, Heighway, J, Hasleton, PS, Altermatt, HJ, Ryder, WD, Cerny, T & Thatcher, N (1996). Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 73: 294–300.
Callender, T, el-Naggar, AK, Lee, MS, Frankenthaler, R, Luna, MA & Batsakis, JG (1994). PRAD-1 (CCND1)/cyclin D1 oncogne amplification in primary head and neck squamous cell carcinoma. Cancer 74: 152–158.
Caputi, M, De Luca, L, Papaccio, G, D’Aponte, A, Cavallotti, I, Scala, P, Scarano, F, Manna, M, Gualdiero, L & De Luca, B (1997). Prognostic role of cyclin D1 in non small cell lung cancer: an immunohistochemical analysis. Eur J Histochem 41: 133–138.
de Vita, VT Jr, Hellman, S & Rosenberg, SA (1997). Cancer: Principles and Practices of Oncology. 5th edn, pp. 858–911 Lippincott: Philadelphia
Fontanini, G, Vignati, S, Bigini, D, Mussi, A, Lucchi, M, Angeletti, CA, Basolo, F & Bevilacqua, G (1995). Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small cell lung cancer. Br J Cancer 71: 1003–1007.
Gillett, C, Fantl, V, Smith, R, Fisher, C, Bartek, J, Dickson, C, Barnes, D & Peters, G (1994). Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54: 1812–1817.
Izbicki, JR, Passlick, B, Hosch, SB, Kubuschock, B, Schneider, C, Busch, C, Knoefel, WT, Thetter, O & Pantel, K (1996). Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg 112: 623–630.
Jares, P, Fernandez, PL, Campo, E, Nadal, A, Bosch, F, Aiza, G, Nayach, I, Traserra, J & Cardesa, A (1994). PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 54: 4813–4817.
Jiang, W, Kahn, SM, Tomita, N, Zhang, YJ, Lu, SH & Weinstein, IB (1992). Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52: 2980–2983.
Kastan, MB & Tooze, J (1997). Checkpoint Controls and Cancer. Cancer Surveys, Vol 29, pp. 7–24. Cold Spring Harbor Laboratory Press: New York
Kayser, K, Bulzebruk, H, Probst, G & Vogt-Moykopf, I (1987). Retrospective and prospective tumor staging evaluating prognostic factors in operated bronchus carcinoma patients. Cancer 59: 355–361.
Kern, JA, Schwartz, DA, Nordberg, JE, Weiner, DB, Greene, MI, Torney, L & Robinson, RA (1990). p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50: 5184–5187.
Kern, JA, Slebos, RJ, Top, B, Rodenhuis, S, Lager, D, Robinson, RA, Weiner, D & Schwartz, DA (1994). C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93: 516–520.
Kwa, HB, Michalides, RJ, Dijkman, JH & Mooi, WJ (1996). The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer. Lung Cancer 14: 207–217.
Lovec, H, Sewing, A, Lucibello, FC, Muller, R & Moroy, T (1994). Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 9: 323–326.
Lukas, J, Pagano, M, Staskova, Z, Draetta, G & Bartek, J (1994). Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumor cell lines. Oncogene 9: 707–718.
Mate, JL, Ariza, A, Aracil, C, Lopez, D, Isamat, M, Perez-Piteira, J & Navas-Palacios, JJ (1996). Cyclin D1 overexpression in non-small cell lung carcinoma: correlation with Ki67 labelling index and poor cytoplasmic differentiation. J Pathol 180: 395–399.
McIntosh, GG, Anderson, JJ, Milton, I, Steward, M, Parr, AH, Thomas, MD, Henry, JA, Angus, B, Lennard, TW & Horne, CH (1995). Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11: 885–891.
Michalides, R, van Veelen, N, Hart, A, Loftus, B, Wientjens, E & Balm, A (1995). Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55: 975–978.
Mitsudomi, T, Steinberg, SM, Oie, HK, Mulshine, JL, Phelps, R, Viallet, J, Pass, H, Minna, JD & Gazdar, AF (1991). ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51: 4999–5002.
Mitsudomi, T, Oyama, T, Kusano, T, Osaki, T, Nakanishi, R & Shirakusa, T (1993). Mutation of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 85: 2018–2023.
Motokura, T & Arnold, A (1993). Cyclins and oncogenesis. Biochem Biophys Acta 1155: 63–78.
Mountain, CF (1986). A new international staging system for lung cancer. Chest 89: 225S–233S.
Mountain, CF, Lukeman, JM, Hammer, SP, Chamberlain, DW, Coulson, WF, Page, DL, Victor, TA & Weiland, LH (1987). Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol 35: 147–156.
Muller, D, Millon, R, Lidereau, R, Engelmann, A, Bronner, G, Flesch, H, Eber, M, Methlin, G & Abecassis, J (1994). Frequent amplification of 11q13 DNA markers associated with lymph node involvement in head and neck squamous cell carcinomas. Eur J Cancer B Oral Oncol 30B, 2 113–120.
Nishida, N, Fukuda, Y, Komeda, T, Kita, R, Sando, T, Furukawa, M, Amenomori, M, Shibagaki, I, Nakao, K, Ikenaga, M & Ishizaki, K (1994). Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 54: 3107–3110.
Naruke, T, Goya, T, Tsuchiya, R & Suemasu, K (1988). Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 96: 440–447.
Pezzella, F, Turley, H, Kuzu, I, Tungekar, MF, Dunnill, MS, Pierce, CB, Harris, A, Gatter, KC & Mason, DY (1993). bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329: 690–694.
Proctor, AJ, Coombs, LM, Cairns, JP & Knowles, MA (1991). Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene 6: 789–795.
Rosvold, E (1996). Prognostic factors for patients with non-small cell lung cancer. In: Current Problems in Cancer. Newer Aspects in the Diagnosis, Treatment, and Prevention of Non-small-cell Lung Cancer. Part II, Williams SD, Goulet R and Thomas G (eds), pp. 272–278. Mosby: Missouri
Schuuring, E, Verhoeven, E, van Tinteren, H, Peterse, JL, Nunnink, B, Thunnissen, FB, Devilee, P, Cornelisse, CJ, van de Vijver, MJ & Mooi, WJ (1992). Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 52: 5229–5234.
Shay, JW, Wright, WE, Brasiskyte, D & Van der Haegen, BA (1993). E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene 8: 1407–1413.
Shin, KY, Kong, G, Kim, WS, Lee, TY, Woo, YN & Lee, JD (1997). Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer 75: 1788–1792.
Simpson, JF, Quan, DE, O’Malley, F, Odom-Maryon, T & Clarke, PE (1997). Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol 151: 161–168.
Tateishi, M, Ishida, T, Mitsudomi, T, Kaneko, S & Sugimachi, K (1991). Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27: 1372–1375.
Wang, TC, Cardiff, RD, Zukerberg, L, Lees, E, Arnold, A & Schmidt, EV (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369: 669–671.
Xu, HJ, Quinlan, DC & Davidson, AG (1994). Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 86: 695–699.
Zhang, YJ, Jiang, W, Chen, CJ, Lee, CS, Kahn, SM, Santella, RM & Weinstein, IB (1993). Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 196: 1010–1016.
Zukerberg, LR, Yang, WI, Arnold, A & Harris, NL (1995a). Cyclin D1 (PRAD1) expression in non-Hodgkin’s lymphomas. Detection by immunohistochemistry. Am J Clin Pathol 103: 756–760.
Zukerberg, LR, Yang, WI, Gadd, M, Thor, AD, Koerner, FC, Schmidt, EV & Arnold, A (1995b). Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol 8: 560–567.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keum, J., Kong, G., Yang, S. et al. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer 81, 127–132 (1999). https://doi.org/10.1038/sj.bjc.6690661
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690661
Keywords
This article is cited by
-
Immunohistochemical expression of Cyclin D1 among Sudanese patients diagnosed with benign and malignant prostatic lesions
BMC Research Notes (2020)
-
MicroRNA-92 promotes invasion and chemoresistance by targeting GSK3β and activating Wnt signaling in bladder cancer cells
Tumor Biology (2016)
-
A carbazole alkaloid deactivates mTOR through the suppression of rictor and that induces apoptosis in lung cancer cells
Molecular and Cellular Biochemistry (2015)
-
Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer
Cancer Immunology, Immunotherapy (2013)
-
CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis
Tumor Biology (2012)
